According to the World Health Organization, by 2020, about 14.1% of the global population will suffer from some form of neurologic disorder. The neurological field has a clinical need for innovations in treatment of all major neurological diseases and in particular those affecting the elderly. An increase in the geriatric population base worldwide, rising investments in R&D, and a deeper understanding of neurologic diseases are aiding the growth of the neurotherapeutic drugs market globally. The aged are more prone to brain disorders – this thus makes the growing geriatric population a high-impact driver for the demand for and sales of neurotherapeutic drugs worldwide.
We are looking for assets in all major areas including Alzheimer’s disease, dementia, migraine, Huntington’s disease, movement disorders, epilepsy and others.